Cite
HARVARD Citation
Goodall, R. et al. (2022). Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 400 (10366), pp. 1858-1868. [Online].